Open AccessLupus anticoagulant in human immunodeficiency virus -infected patients on highly active antiretroviral therapy
Author(s) -
OA Awodu,
Edeghonghon Olayemi,
GN Bazuaye,
A N Onunu
Publication year - 2010
Publication title -
indian journal of pathology and microbiology/indian journal of pathology and microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.217
H-Index - 31
eISSN - 0974-5130
pISSN - 0377-4929
DOI - 10.4103/0377-4929.59182
Subject(s) - lupus anticoagulant , medicine , partial thromboplastin time , nigerians , clotting time , human immunodeficiency virus (hiv) , prothrombin time , immunology , clotting factor , coagulation testing , gastroenterology , antibody , coagulation , political science , law
Lupus anticoagulant (LA) is a heterogeneous group of antibodies that causes a variety of clinical and laboratory effects; has been described in infections such as human immunodeficiency virus. LA has not been previously described in Nigerians with human immunodeficiency virus infection on highly active antiretroviral therapy (HAART).